BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 28853885)

  • 1. Discovery of Fragment-Derived Small Molecules for in Vivo Inhibition of Ketohexokinase (KHK).
    Huard K; Ahn K; Amor P; Beebe DA; Borzilleri KA; Chrunyk BA; Coffey SB; Cong Y; Conn EL; Culp JS; Dowling MS; Gorgoglione MF; Gutierrez JA; Knafels JD; Lachapelle EA; Pandit J; Parris KD; Perez S; Pfefferkorn JA; Price DA; Raymer B; Ross TT; Shavnya A; Smith AC; Subashi TA; Tesz GJ; Thuma BA; Tu M; Weaver JD; Weng Y; Withka JM; Xing G; Magee TV
    J Med Chem; 2017 Sep; 60(18):7835-7849. PubMed ID: 28853885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Michaelis-like complex of mouse ketohexokinase isoform C.
    Gasper WC; Gardner S; Ross A; Oppelt SA; Allen KN; Tolan DR
    Acta Crystallogr D Struct Biol; 2024 Jun; 80(Pt 6):377-385. PubMed ID: 38805243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ketohexokinase-A deficiency attenuates the proliferation via reducing β-catenin in gastric cancer cells.
    Ma G; Liu S; Cai F; Liang H; Deng J; Zhang R; Cai M
    Exp Cell Res; 2024 May; 438(1):114038. PubMed ID: 38614422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ketohexokinase knockout mice, a model for essential fructosuria, exhibit altered fructose metabolism and are protected from diet-induced metabolic defects.
    Miller CO; Yang X; Lu K; Cao J; Herath K; Rosahl TW; Askew R; Pavlovic G; Zhou G; Li C; Akiyama TE
    Am J Physiol Endocrinol Metab; 2018 Sep; 315(3):E386-E393. PubMed ID: 29870677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Divergent effects of glucose and fructose on hepatic lipogenesis and insulin signaling.
    Softic S; Gupta MK; Wang GX; Fujisaka S; O'Neill BT; Rao TN; Willoughby J; Harbison C; Fitzgerald K; Ilkayeva O; Newgard CB; Cohen DE; Kahn CR
    J Clin Invest; 2017 Nov; 127(11):4059-4074. PubMed ID: 28972537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of PF-06835919: A Potent Inhibitor of Ketohexokinase (KHK) for the Treatment of Metabolic Disorders Driven by the Overconsumption of Fructose.
    Futatsugi K; Smith AC; Tu M; Raymer B; Ahn K; Coffey SB; Dowling MS; Fernando DP; Gutierrez JA; Huard K; Jasti J; Kalgutkar AS; Knafels JD; Pandit J; Parris KD; Perez S; Pfefferkorn JA; Price DA; Ryder T; Shavnya A; Stock IA; Tsai AS; Tesz GJ; Thuma BA; Weng Y; Wisniewska HM; Xing G; Zhou J; Magee TV
    J Med Chem; 2020 Nov; 63(22):13546-13560. PubMed ID: 32910646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein crystallography and drug discovery: recollections of knowledge exchange between academia and industry.
    Blundell TL
    IUCrJ; 2017 Jul; 4(Pt 4):308-321. PubMed ID: 28875019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacologic inhibition of ketohexokinase prevents fructose-induced metabolic dysfunction.
    Gutierrez JA; Liu W; Perez S; Xing G; Sonnenberg G; Kou K; Blatnik M; Allen R; Weng Y; Vera NB; Chidsey K; Bergman A; Somayaji V; Crowley C; Clasquin MF; Nigam A; Fulham MA; Erion DM; Ross TT; Esler WP; Magee TV; Pfefferkorn JA; Bence KK; Birnbaum MJ; Tesz GJ
    Mol Metab; 2021 Jun; 48():101196. PubMed ID: 33667726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acetyl-CoA Carboxylase Inhibition Improves Multiple Dimensions of NASH Pathogenesis in Model Systems.
    Ross TT; Crowley C; Kelly KL; Rinaldi A; Beebe DA; Lech MP; Martinez RV; Carvajal-Gonzalez S; Boucher M; Hirenallur-Shanthappa D; Morin J; Opsahl AC; Vargas SR; Bence KK; Pfefferkorn JA; Esler WP
    Cell Mol Gastroenterol Hepatol; 2020; 10(4):829-851. PubMed ID: 32526482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation.
    Bates J; Vijayakumar A; Ghoshal S; Marchand B; Yi S; Kornyeyev D; Zagorska A; Hollenback D; Walker K; Liu K; Pendem S; Newstrom D; Brockett R; Mikaelian I; Kusam S; Ramirez R; Lopez D; Li L; Fuchs BC; Breckenridge DG
    J Hepatol; 2020 Oct; 73(4):896-905. PubMed ID: 32376414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ketohexokinase inhibition improves NASH by reducing fructose-induced steatosis and fibrogenesis.
    Shepherd EL; Saborano R; Northall E; Matsuda K; Ogino H; Yashiro H; Pickens J; Feaver RE; Cole BK; Hoang SA; Lawson MJ; Olson M; Figler RA; Reardon JE; Nishigaki N; Wamhoff BR; Günther UL; Hirschfield G; Erion DM; Lalor PF
    JHEP Rep; 2021 Apr; 3(2):100217. PubMed ID: 33490936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ketohexokinase C blockade ameliorates fructose-induced metabolic dysfunction in fructose-sensitive mice.
    Lanaspa MA; Andres-Hernando A; Orlicky DJ; Cicerchi C; Jang C; Li N; Milagres T; Kuwabara M; Wempe MF; Rabinowitz JD; Johnson RJ; Tolan DR
    J Clin Invest; 2018 Jun; 128(6):2226-2238. PubMed ID: 29533924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fructose Metabolism in Cancer.
    Krause N; Wegner A
    Cells; 2020 Dec; 9(12):. PubMed ID: 33302403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ketohexokinase-A acts as a nuclear protein kinase that mediates fructose-induced metastasis in breast cancer.
    Kim J; Kang J; Kang YL; Woo J; Kim Y; Huh J; Park JW
    Nat Commun; 2020 Oct; 11(1):5436. PubMed ID: 33116123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KHK-A promotes the proliferation of oesophageal squamous cell carcinoma through the up-regulation of PRPS1.
    Yang J; Yang S; Wang Q; Pang J; Wang Y; Wang H; Fu X
    Arab J Gastroenterol; 2021 Mar; 22(1):40-46. PubMed ID: 32928708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aldolase B-Mediated Fructose Metabolism Drives Metabolic Reprogramming of Colon Cancer Liver Metastasis.
    Bu P; Chen KY; Xiang K; Johnson C; Crown SB; Rakhilin N; Ai Y; Wang L; Xi R; Astapova I; Han Y; Li J; Barth BB; Lu M; Gao Z; Mines R; Zhang L; Herman M; Hsu D; Zhang GF; Shen X
    Cell Metab; 2018 Jun; 27(6):1249-1262.e4. PubMed ID: 29706565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Practice Guidelines for the Diagnosis and Management of Hereditary Fructose Intolerance.
    Úbeda F; Santander S; Luesma MJ
    Diseases; 2024 Feb; 12(3):. PubMed ID: 38534968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fructose induced KHK-C can increase ER stress independent of its effect on lipogenesis to drive liver disease in diet-induced and genetic models of NAFLD.
    Park SH; Helsley RN; Fadhul T; Willoughby JLS; Noetzli L; Tu HC; Solheim MH; Fujisaka S; Pan H; Dreyfuss JM; Bons J; Rose J; King CD; Schilling B; Lusis AJ; Pan C; Gupta M; Kulkarni RN; Fitzgerald K; Kern PA; Divanovic S; Kahn CR; Softic S
    Metabolism; 2023 Aug; 145():155591. PubMed ID: 37230214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ketohexokinase-C regulates global protein acetylation to decrease carnitine palmitoyltransferase 1a-mediated fatty acid oxidation.
    Helsley RN; Park SH; Vekaria HJ; Sullivan PG; Conroy LR; Sun RC; Romero MDM; Herrero L; Bons J; King CD; Rose J; Meyer JG; Schilling B; Kahn CR; Softic S
    J Hepatol; 2023 Jul; 79(1):25-42. PubMed ID: 36822479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fructose Induced KHK-C Increases ER Stress and Modulates Hepatic Transcriptome to Drive Liver Disease in Diet-Induced and Genetic Models of NAFLD.
    Park SH; Helsley RN; Fadhul T; Willoughby JLS; Noetzli L; Tu HC; Solheim MH; Fujisaka S; Pan H; Dreyfuss JM; Bons J; Rose J; King CD; Schilling B; Lusis AJ; Pan C; Gupta M; Kulkarni RN; Fitzgerald K; Kern PA; Divanovic S; Kahn CR; Softic S
    bioRxiv; 2023 Jan; ():. PubMed ID: 36747758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.